Regencell Bioscience Holdings annual free cash flow
2020
2022
2023
2024
2025
Regencell Bioscience Holdings Free Cash Flow (FCF) History (RGC)
Regencell Bioscience Holdings reported −$3.3M in free cash flow for fiscal 2025, an increase of $740,798 from the previous fiscal year.
View full Regencell Bioscience Holdings company overviewRegencell Bioscience Holdings free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-06-30 | −$3.3M | $740,798 | — | — |
| 2024 | 2024-06-30 | −$4.0M | $983,278 | — | — |
| 2023 | 2023-06-30 | −$5.0M | $1.1M | — | — |
| 2022 | 2022-06-30 | −$6.0M | −$5.2M | — | — |
| 2020 | 2020-06-30 | −$844,410 | — | — | — |
Regencell Bioscience Holdings quarterly free cash flow
No reported data
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|
Regencell Bioscience Holdings free cash flow growth trends
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Regencell Bioscience Holdings filings at SEC.gov ↗